New Drug May Help Control Hypo Risks
Heralded as the best thing since insulin, pramilitide, a new drug being studied by two U.S. research centers, may soon be available to help type 1 individuals reduce hypoglycemia risks. The St. James Center for Diabetes in Chicago and Tulane University Medical Center in New Orleans both recently launched studies of the drug's effectiveness in improving glucose control and lessening the risk of hypoglycemia in type 1 patients. In preliminary studies, patients not only improved glucose control while using pramilitide, but had better cholesterol profiles and lost weight. The current studies seek to confirm the earlier findings.
Both the St. James Center and Tulane University are currently seeking candidates to participate in their studies. Participants must have been taking insulin for at least 12 months, be in good health, have had a stable insulin regimen for the past two months, and be willing to take additional injections of the experimental drug as an adjunct to insulin.
Contact Robyn Ekings in New Orleans at (504) 588-5221 or Christine Beebe in Chicago at (708) 709-2010 for more information.Click Here To View Or Post Comments